Buyback of Class B shares in Essity during week 1, 2025
STOCKHOLM, Jan. 7, 2025 /PRNewswire/ — Between December 30, 2024, and January 3, 2025, Essity Aktiebolag (publ) repurchased a total of 162,000 own Class B shares (ISIN: SE0009922164) under the framework of the buyback program as resolved by the Board of Directors. The share purchase is part o
Buyback of Class B shares in Essity during week 1, 2025
STOCKHOLM, Jan. 7, 2025 /PRNewswire/ — Between December 30, 2024, and January 3, 2025, Essity Aktiebolag (publ) repurchased a total of 162,000 own Class B shares (ISIN: SE0009922164) under the framework of the buyback program as resolved by the Board of Directors. The share purchase is part o
Global Edtech Breakthrough: Mathleaks Introduces MathVizy, the First Math-Dedicated AI
STOCKHOLM, Jan. 7, 2025 /PRNewswire/ — The Swedish edtech innovator Mathleaks has launched MathVizy, the world’s first AI designed exclusively for math. For the first time, users can visualize step-by-step solutions with unparalleled clarity. “Our AI will revolutionize how math is
Global Edtech Breakthrough: Mathleaks Introduces MathVizy, the First Math-Dedicated AI
STOCKHOLM, Jan. 7, 2025 /PRNewswire/ — The Swedish edtech innovator Mathleaks has launched MathVizy, the world’s first AI designed exclusively for math. For the first time, users can visualize step-by-step solutions with unparalleled clarity. “Our AI will revolutionize how math is
U.S. FDA Granted Priority Review to Dizal’s Sunvozertinib New Drug Application
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins Sunvozertinib’s NDA was submitted based on the multinational pivotal WU-KONG1 Part B study, the results of which were presented at
U.S. FDA Granted Priority Review to Dizal’s Sunvozertinib New Drug Application
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins Sunvozertinib’s NDA was submitted based on the multinational pivotal WU-KONG1 Part B study, the results of which were presented at
Prytime Medical Announces First in European Use of New Extended Safe Occlusion Time Catheter
BOERNE, Texas, Jan. 7, 2025 /PRNewswire/ — Prytime Medical, The REBOA Company™, proudly announces the first civilian use of its pREBOA-PRO™ catheter in the European Union, following the device’s receipt of CE Mark approval. The pREBOA-PRO™ catheter is already approved in the Unite
Indian Hospitality Excellence Awards 2024: Honoring Outstanding Leadership and Talent in the Industry
DUBAI, UAE, Jan. 7, 2025 /PRNewswire/ — The prestigious Indian Hospitality Excellence Awards 2024 unfolded with grandeur at the Crowne Plaza Hotel Greater Noida on January 4, 2025. Marking its fourth successful edition, the event brought together over 200 professionals from across India’
Tech Mahindra Tops India and Achieves Second Place Globally in the S&P Dow Jones Sustainability Indices 2024 for TSV IT Services Segment
PUNE, India and NEW YORK, Jan. 7, 2025 /PRNewswire/ — Tech Mahindra (NSE: TECHM), a leading global provider of technology consulting and digital solutions to enterprises across industries, has announced its recognition as a global sustainability leader by S&P Dow Jones Sustainability In
Siemens launches new program to empower startups with cutting-edge technology
Siemens for Startups program to streamline the collaboration process and facilitate partnerships with new innovative companies Siemens to collaborate with Amazon Web Services (AWS) to deliver access to Siemens Xcelerator ecosystem and accelerate innovation at startups MUNICH, Jan. 7, 2025 /PRNewswi
